Payment overview · 2025
General Payments
$3,588.81
60 reported records · 19 companies
Healthcare provider profile · identity verified
Kevin Prier
Allopathic & Osteopathic Physicians|Internal Medicine · IDAHO FALLS, ID · NPI 1801393798
Verified facts
What the public records show
CMS Open Payments records show Kevin Prier received $3,588.81 in general payments during 2025 across 60 reported records.
Eli Lilly and Company accounted for 79.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Jardiance by this doctor in 2024.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 15 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Jardiance by this doctor in 2024.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 176 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 585 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 585 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 528 claims for Ozempic by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eli Lilly and Company | Unresolved — no canonical attribution shown | $2,866.31 | 79.9% | 21 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $89.46 | 2.5% | 7 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $88.71 | 2.5% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $76.87 | 2.1% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.14 | 1.9% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $56.24 | 1.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $52.62 | 1.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.39 | 1.3% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $36.94 | 1.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.41 | 0.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.13 | 0.8% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.62 | 0.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.45 | 0.6% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $19.67 | 0.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.07 | 0.5% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $15.64 | 0.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.22 | 0.4% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $14.98 | 0.4% | 1 | 2025 |
| Eton Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.94 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $2,665.47 | 16 |
| Food and Beverage | $923.34 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $91.78 | 5 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $88.71 | 4 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $76.87 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $67.82 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $56.24 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $52.62 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.32 | 4 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $36.94 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $33.10 | 2 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $29.41 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.13 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| ALKINDI Normalized: alkindi |
Drug | Eton Pharmaceuticals, Inc. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| INCRELEX Normalized: increlex |
Drug | Eton Pharmaceuticals, Inc. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| KHINDIVI Normalized: khindivi |
Drug | Eton Pharmaceuticals, Inc. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 202 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 585 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 528 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
202 | 55 |
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 11 recipient NPIs · example record 1186556234 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
202 | 55 |
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 176 supporting records · 33 recipient NPIs · example record 1186466331 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
585 | 105 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
202 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
585 | 105 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
124 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
528 | 113 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 662 | 194 |
| Mounjaro | Tirzepatide | 585 | 105 |
| Ozempic | Semaglutide | 528 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 404 | 125 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 354 | 100 |
| Metformin Hcl Er | Metformin Hcl | 336 | 106 |
| Losartan Potassium | Losartan Potassium | 217 | 59 |
| Metformin Hcl | Metformin Hcl | 216 | 70 |
| Omeprazole | Omeprazole | 212 | 70 |
| Jardiance | Empagliflozin | 202 | 55 |
| Atorvastatin Calcium | Atorvastatin Calcium | 188 | 67 |
| Lisinopril | Lisinopril | 157 | 54 |
| Pioglitazone Hcl | Pioglitazone Hcl | 138 | 47 |
| Novolog Flexpen | Insulin Aspart | 133 | 44 |
| Trulicity | Dulaglutide | 124 | 33 |
| Carvedilol | Carvedilol | 119 | 35 |
| Gabapentin | Gabapentin | 119 | 39 |
| Potassium Chloride | Potassium Chloride | 119 | 29 |
| Humalog Kwikpen U-100 | Insulin Lispro | 115 | 44 |
| Farxiga | Dapagliflozin Propanediol | 108 | 23 |
| Simvastatin | Simvastatin | 108 | 35 |
| Tresiba Flextouch U-100 | Insulin Degludec | 107 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 100 | 32 |
| Glimepiride | Glimepiride | 84 | 28 |
| Furosemide | Furosemide | 83 | 24 |
| Alendronate Sodium | Alendronate Sodium | 79 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 26 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 72 | 28 |
| Ezetimibe | Ezetimibe | 67 | 27 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 66 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 64 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 18 |
| Trazodone Hcl | Trazodone Hcl | 58 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 56 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 52 | 15 |
| Liothyronine Sodium | Liothyronine Sodium | 48 | 17 |
| Humalog | Insulin Lispro | 46 | 15 |
| Calcitriol | Calcitriol | 45 | suppressed |
| Hydrocortisone | Hydrocortisone | 45 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 45 | 15 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 43 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 42 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 41 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 12 |
| Sertraline Hcl | Sertraline Hcl | 40 | 14 |
| Synthroid | Levothyroxine Sodium | 40 | 15 |
| Methimazole | Methimazole | 39 | 14 |
| Pen Needle | Pen Needle, Diabetic | 35 | 21 |
| Allopurinol | Allopurinol | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 33 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 13 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 27 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Novolog | Insulin Aspart | 26 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Cabergoline | Cabergoline | 25 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 25 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Insulin Aspart | Insulin Aspart | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Eliquis | Apixaban | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Fiasp Penfill | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,588.81 · 60 records | Eli Lilly and Company | ALKINDI, Dexcom G6 Transmitter, EVENITY, General - Pain Management, INCRELEX, ISTURISA, JARDIANCE, KHINDIVI, Kerendia, Korlym, LEQVIO, MOUNJARO, Omnipod, Ozempic, QUTENZA, RECORLEV, REZDIFFRA, TEPEZZA, TZIELD, Yorvipath, ZENPEP, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error